Skip to main content
. Author manuscript; available in PMC: 2013 Sep 7.
Published in final edited form as: Mol Neurobiol. 2012 Sep 7;46(1):221–226. doi: 10.1007/s12035-012-8322-5

Figure 4. NPD1 shifts βAAP processing to a non-amyloidogenic pathway.

Figure 4

(A) Control or HNG cells over-expressing βAPPsw were treated with increasing concentrations (0, 50, 100, 500 nM) of NPD1 for 48 h and subjected to Western blot detection of holo-βAPP (βAPP holoenzyme), sAPPα, sAPPβsw, CTFα and CTFβ in comparison to β-actin levels in the same sample; (B) Quantification of gel bands in (A) analyzing βAPP fragments with increasing doses of NPD1. Results are means ± SEM (n=4); *p<0.01 vs. βAPPsw control.